Back to top
more

XOMA Corporation (XOMA)

(Delayed Data from NSDQ)

$18.90 USD

18.90
64,722

+0.44 (2.38%)

Updated Jul 19, 2019 03:58 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.80%
17.93%
9.58%
5.18%
2.03%
10.63%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | A Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

XOMA

Zacks Equity Research

Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XOMA

Zacks Equity Research

Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus

Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.

MRK INCY AGEN XOMA

Zacks Equity Research

Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

XOMA

Zacks Equity Research

Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up?

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XOMA

Zacks Equity Research

Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

XOMA

Zacks Equity Research

AbbVie Presents New Data on Upadacitinib for Crohn's Disease

AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

ABBV XOMA EXEL ENTA

Zacks Equity Research

Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

ACOR XOMA BIIB EXEL

Zacks Equity Research

FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

ABT AGIO CELG XOMA

Zacks Equity Research

Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

AZN AGN XOMA IRWD

Zacks Equity Research

Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

ALKS XOMA BIIB EXEL

Zacks Equity Research

Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.

XOMA EXEL ENTA

Zacks Equity Research

Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.

AGIO CELG XOMA EXEL

Zacks Equity Research

Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses

Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.

RHHBY XOMA EXEL PRTA

Zacks Equity Research

Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.

XOMA EXEL SHPG ENTA

Zacks Equity Research

AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

XOMA EXEL AVEO ENTA

Zacks Equity Research

Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling

Catalyst (CPRX) posts positive results from a recent Type C meeting with the FDA on resubmitting the new drug application for Firdapse in treating Lambert-Eaton myasthenic syndrome.

BMRN XOMA EXEL CPRX

Zacks Equity Research

Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.

VRTX XOMA EXEL CNCE

Zacks Equity Research

ImmunoGen (IMGN) Q4 Loss Wider Than Expected, Revenues Grow

ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.

RHHBY MRK XOMA IMGN

Zacks Equity Research

FDA Okays J&J's Prostate Cancer Drug in First-Line Setting

The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.

PFE JNJ XOMA EXEL

Zacks Equity Research

Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

JNJ XOMA EXEL TBPH

Zacks Equity Research

Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4

Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.

ALXN XOMA EXEL SCMP

Zacks Equity Research

Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

XOMA EXEL KERX SCMP

Zacks Equity Research

Pfizer Files for Xtandi in Early Stage Prostate Cancer

Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.

PFE XOMA EXEL SCMP

Zacks Equity Research

Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod

The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.

PFE AGN XOMA EXEL